Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 11/20 | 0.50 |
| ▸ | MC3R | P41968 | 10/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MC5R | P33032 | 10/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11471836 | 0.76 | MC3R (0.68) | MC4RMC3RNPSR1MEN1KMT2A | |
| SCHEMBL14823280 | 0.74 | TRPM8 (0.41) | MC4RMC3RNPSR1MEN1KMT2A | |
| SCHEMBL11068554 | 0.72 | MC3R (0.74) | MC4RMC3RMEN1KMT2AMC5R | |
| SCHEMBL7846127 | 0.72 | CDK4 (0.60) | MC4RMC3RNPSR1MEN1KMT2A | |
| SCHEMBL14264727 | 0.72 | MC4R (0.71) | MC4RMC3RMEN1KMT2AMC5R | |
| SCHEMBL11066319 | 0.70 | MC4R (0.60) | MC4RMC3RNPSR1MEN1KMT2A | |
| SCHEMBL18229448 | 0.70 | MEN1 (0.85) | MC4RMC3RMEN1KMT2AMC5R | |
| SCHEMBL30777136 | 0.70 | MEN1 (0.85) | MC4RMC3RMEN1KMT2AMC5R | |
| SCHEMBL5807879 | 0.69 | KMT2A (0.55) | MC4RMC3RMEN1KMT2AMC5R | |
| Hydrochloric Acid SCHEMBL7858078 | 0.68 | CDK4 (0.58) | MC4RMC3RMEN1KMT2AMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410138-B2 | Compounds for activating TGF-beta signaling | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410138-B2 | Compounds for activating TGF-beta signaling | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410138-B2 | Compounds for activating TGF-beta signaling | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120095000-A1 | COMPOUNDS FOR ACTIVATING TGF-BETA SIGNALING | SRI INTERNATIONAL (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095000-A1 | COMPOUNDS FOR ACTIVATING TGF-BETA SIGNALING | SRI INTERNATIONAL (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095000-A1 | COMPOUNDS FOR ACTIVATING TGF-BETA SIGNALING | SRI INTERNATIONAL (US) | 2012-04-19 | — | — | US | disclosed |
| US-8097645-B2 | Compounds for activating TGF-β signaling | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097645-B2 | Compounds for activating TGF-β signaling | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097645-B2 | Compounds for activating TGF-β signaling | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-01-17 | — | — | US | disclosed |
| US-20090143394-A1 | COMPOUNDS FOR ACTIVATING TGF-BETA SIGNALING | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143394-A1 | COMPOUNDS FOR ACTIVATING TGF-BETA SIGNALING | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143394-A1 | COMPOUNDS FOR ACTIVATING TGF-BETA SIGNALING | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143394-A1 | COMPOUNDS FOR ACTIVATING TGF-BETA SIGNALING | TGFB1, TGFB2, TGFBR1 | MC4R 3092/4885MC3R 3855/4885NPSR1 2859/4885 |
| US-20120095000-A1 | COMPOUNDS FOR ACTIVATING TGF-BETA SIGNALING | TGFB1, TGFB2, TGFBR1 | MC4R 3092/4885MC3R 3855/4885NPSR1 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.